Inventaire - your friends and communities are your best library

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

লেখক

Maria T Voso

Luana Fianchi

Marianna Criscuolo

Francesco Spina

এতে প্রকাশিত: Annals of Oncology

তারিখে প্রকাশিত: 2017-07-01

ভাষা: ইংরেজি ভাষা

মূল বিষয়: acute myeloid leukemia

Cites articles 20

তারিখ

শিরোনাম

লেখকগণ

2016-09-20

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

Liesbeth De Wreede, Liisa Volin, Uwe Platzbecker
2016-05-19

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Clara D. Bloomfield, James W Vardiman, Michelle M Le Beau
2015-06-21

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Pellegrino Musto, Maria T Voso, Luana Fianchi, Marianna Criscuolo, Maria Antonietta Aloe Spiriti, Francesco Buccisano, Adriano Venditti, Pasquale Niscola, Livio Pagano, Luca Maurillo, Andrea Tendas, Alfonso Piciocchi, Massimo Breccia, Susanna Fenu, Anna Lina Piccioni, Gina Zini, Roberto Latagliata, Giovanna Mansueto, Alberto Fragasso
2015-02-13

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

Raphaël Porcher, Eric Wattel, Laure Vincent
2014-02-20

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

Emanuele Angelucci, Paolo Bernasconi, Alberto Bosi, Massimo Bernardi
2014-12-01

A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia.

He Huang, Yener Koc, Gerhard Ehninger
2014-08-01

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party

Nicolaas Schaap, Liisa Volin, Johan Maertens, Enric Carreras
2014-08-04

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

Coleman Lindsley, Brenton G Mar, Jerome Ritz, Joseph H Antin, Edwin P Alyea, Robert J Soiffer, Philippe Armand, Corey S Cutler, John Koreth, Kristen E Stevenson, Donna Neuberg
2013-06-17

Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
2013-04-12

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

Eva Hellström-Lindberg, Pierre Fenaux
2012-06-27

Revised international prognostic scoring system for myelodysplastic syndromes

Guillermo F Sanz, Hagop Kantarjian, Pierre Fenaux, Guillermo Garcia-Manero, Ulrich Germing, Michelle M Le Beau, Reinhard Stauder, Jaroslaw P. Maciejewski, Wolfgang R Sperr, Everett Peter Greenberg, Mikkael A Sekeres, Sudhir Tauro, Luca Malcovati, Heinz Tuechler, Julie Schanz, Andrea Kuendgen, Marilyn L Slovak, Yasushi Miyazaki, Michael Pfeilstöcker, Teresa Vallespi, Arjan A van de Loosdrecht
2012-01-16

Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.

Frederick R. Appelbaum, Hans Joachim Deeg, Elihu Estey, Bart L Scott, Aaron T Gerds
2012-07-05

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Uwe Platzbecker, Rainer Storb, Brenda M Sandmaier, Frederick R. Appelbaum, Hans Joachim Deeg, Mohamed L Sorror, Jerald P Radich, Wendy Wilson, Bart L Scott, David Myerson, Howard M Shulman, Boglarka Gyurkocza, Aravind Ramakrishnan, Derek L Stirewalt
2012-05-11

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine

Pierre Fenaux, Gerhard Ehninger, Martin Bornhäuser, Ulrich Germing, Uwe Platzbecker, Hans Joachim Deeg, Johannes Schetelig, Dietrich W Beelen, Jürgen Finke, Rudolf Trenschel, Bart L Scott, Guido Kobbe, Kerstin Schaefer-Eckart, Lionel Adès
2010-03-08

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

Robert Peter Gale, Sergio Giralt, Martin S. Tallman, Hillard M. Lazarus, Edmund K Waller, Daniel J Weisdorf, Luis Isola, Richard Maziarz, John DiPersio, Armand Keating, Theresa Hahn
2010-05-21

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

Eva Hellström-Lindberg, Petra Muus, Alois Gratwohl, Stefan Suciu, Harry Schouten
2010-08-05

Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome
2009-03

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Eva Hellström-Lindberg, Valeria Santini, Guillermo F Sanz, Alan F List, John C Byrd, Aristoteles A N Giagounidis, Norbert Gattermann, Jay Backstrom, Lewis B Silverman
2005-10-15

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Rainer Storb, Brenda M Sandmaier, Barry E Storer, David G. Maloney, Mohamed L Sorror
1989-03-01

Optimal two-stage designs for phase II clinical trials.

নিবন্ধ - wd:Q38860919

জায়ে আপনাকে স্বাগত

the library of your friends and communities

আরো জানুন